Provided by Tiger Trade Technology Pte. Ltd.

Tarsus Pharmaceuticals, Inc.

78.09
-0.9400-1.19%
Post-market: 78.090.00000.00%19:30 EDT
Volume:710.97K
Turnover:55.55M
Market Cap:3.43B
PE:-72.14
High:79.10
Open:78.67
Low:77.33
Close:79.03
52wk High:91.53
52wk Low:53.85
Shares:43.88M
Float Shares:35.64M
Volume Ratio:1.21
T/O Rate:1.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0824
EPS(LYR):-1.5900
ROE:-13.68%
ROA:-5.48%
PB:9.88
PE(LYR):-49.11

Loading ...

A Look At Tarsus Pharmaceuticals (TARS) Valuation After TP-05 Phase 2 Lyme Disease Trial Begins

Simply Wall St.
·
Apr 02

Tarsus Pharmaceuticals (TARS) Receives a Buy from LifeSci Capital

TIPRANKS
·
Apr 01

Buy Rating Backed by Blockbuster Xdemvy Launch and TP-05 Lyme Prevention Opportunity

TIPRANKS
·
Apr 01

Tarsus Pharmaceuticals Doses First Participant in Phase 2 Lyme Disease Prevention Study

MT Newswires Live
·
Mar 31

BRIEF-Tarsus Doses First Participant In Calliope, A Phase 2 Clinical Trial Of Tp-05 (Lotilaner)

Reuters
·
Mar 31

Tarsus Pharmaceuticals Inc - Enrollment to Complete in 2026 Tick Season, Topline Results Expected First Half 2027

THOMSON REUTERS
·
Mar 31

Barclays Reaffirms Their Buy Rating on Tarsus Pharmaceuticals (TARS)

TIPRANKS
·
Mar 30

Analysts’ Top Healthcare Picks: Tarsus Pharmaceuticals (TARS), IDEAYA Biosciences (IDYA)

TIPRANKS
·
Mar 28

Mizuho Lifts Price Target on Tarsus Pharmaceuticals to $101 From $100, Keeps Outperform Rating

MT Newswires Live
·
Mar 26

Tarsus Pharmaceuticals price target raised to $101 from $100 at Mizuho

TIPRANKS
·
Mar 26

Analysts Conflicted on These Healthcare Names: Cibus (CBUS), Arrowhead Pharmaceuticals (ARWR) and Tarsus Pharmaceuticals (TARS)

TIPRANKS
·
Mar 26

Tarsus COO Neervannan Seshadri disposes of USD 199,516 in common shares

Reuters
·
Mar 25

BUZZ-Tarsus rises as China approval unlocks $15 million milestone for eye drug

Reuters
·
Mar 23

Tarsus TP-03 wins China NMPA approval, triggering USD 15 million milestone payment

Reuters
·
Mar 23

Tarsus Pharmaceuticals Inc - Eligible for Additional Milestones and Tiered Royalties for Tp-03 in Greater China

THOMSON REUTERS
·
Mar 23

Tp-03 (Lotilaner Ophthalmic Solution) 0.25% NOW Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus

THOMSON REUTERS
·
Mar 23